Metal complexes for use in medical and therapeutic applications
AssigneeThe Procter & Gamble Company
InventorChristopher Mark Perkins
Life of this patent
Estimating the term…
Abstract
The first aspect of the present invention relates to transition metal complexes having the formula: wherein M is a radioactive metal having a valence of +2, +3, +4, or +5; m+ designates the charge of the metal complex, each R is independently C1-C8 linear or branched alkyl, a fifth ligand, and mixtures thereof; B is a bridging unit which comprises at least 2 carbon atoms; L is a pharmaceutically acceptable ligand; X is a pharmaceutically compatible anion in sufficient amount to provide electronic neutrality. The complexes of the present invention are suitable for use in diagnostic, therapeutic or radiotherapeutic or chemotherapeutic compositions for visualization, therapy, chemotherapy or radiotherapy of tissues or organs.
Claims28
A transition metal complex having the formula:
- wherein M is a radioactive metal having a valence of +2 or +3;
- m+ designates the charge of the metal complex, each R is independently C1-C8 linear or branched alkyl, a fifth ligand, and mixtures thereof;
- B is a bridging unit selected from the group consisting of 2-butenylene, 2,3-dimethylbutenylene, 1,2-xylyl, substituted 1,2-xylyl, and mixtures thereof;
- L is a pharmaceutically acceptable ligand;
- X is a pharmaceutically compatible anion in sufficient amount to provide electronic neutrality.
A diagnostic, therapeutic or radiotherapeutic or chemotherapeutic composition for visualization, therapy, chemotherapy or radiotherapy of tissues or organs comprising:
- a) an effective amount of a transition metal radionuclide complex having the formula:
- wherein M is a radioactive metal having a valence of +2, +3, +4, or +5;
- each R is independently C1-C8 linear or branched alkyl, a fifth ligand, and mixtures thereof;
- wherein B is a bridging unit selected from the group consisting of 2-butenylene, 2,3-dimethylbutenylene, 1,2-xylyl, substituted 1,2-xylyl, and mixtures thereof;
- L is a pharmaceutically acceptable ligand;
- X is a pharmaceutically compatible anion in sufficient amount to provide electronic neutrality;
- and
- b) the balance a pharmaceutically acceptable carrier and other adjunct ingredients.
A diagnostic, therapeutic or radiotherapeutic or chemotherapeutic composition for visualization, therapy, chemotherapy or radiotherapy of tissues or organs comprising:
- a) an effective amount of a transition metal radionuclide complex having the formula:
- wherein M is a radioactive metal having a valence of 2, +3, +4, or +5;
- m+ designates the charge of the metal complex, each R is independently C1-C8 linear or branched alkyl, a fifth ligand, and mixtures thereof;
- wherein B is a bridging unit selected from the group consisting of 2-butenylene, 2,3-dimethylbutenylene, 1,2-xylyl, substituted 1,2-xylyl, and mixtures thereof;
- L is a pharmaceutically acceptable ligand;
- X is a pharmaceutically compatible anion in sufficient amount to provide electronic neutrality;
- and
- b) the balance a pharmaceutically acceptable carrier and other adjunct ingredients.
A method for providing a diagnostic, therapeutic or radiotherapeutic or chemotherapeutic composition for visualization, therapy, chemotherapy or radiotherapy of tissues or organs comprising the steps of administering a composition comprising:
- a) an effective amount of a transition metal radionuclide complex having the formula:
- wherein M is a radioactive metal having a valence of 2, +3, +4, or +5;
- m+ designates the charge of the metal complex, each R is independently C1-C8 linear or branched alkyl, and mixtures thereof;
- wherein B is a bridging unit selected from the group consisting of 2-butenylene, 2,3-dimethylbutenylene, 1,2-xylyl, substituted 1,2-xylyl, and mixtures thereof;
- L is a pharmaceutically acceptable ligand;
- X is a pharmaceutically compatible anion in sufficient amount to provide electronic neutrality;
- and
- b) the balance a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.